Paul Mahon Biography and Net Worth
Mr. Mahon has served as General Counsel and Corporate Secretary of United Therapeutics since its inception in 1996. In 2001, Mr. Mahon joined United Therapeutics full-time as Senior Vice President, General Counsel and Corporate Secretary. In 2003, Mr. Mahon was promoted to Executive Vice President, General Counsel and Corporate Secretary. Prior to 2001, he served United Therapeutics, beginning with its formation in 1996, in his capacity as principal and managing partner of a law firm specializing in technology and media law.
What is Paul A. Mahon's net worth?
The estimated net worth of Paul A. Mahon is at least $7.68 million as of September 22nd, 2022. Mr. Mahon owns 36,397 shares of United Therapeutics stock worth more than $7,682,679 as of September 29th. This net worth approximation does not reflect any other assets that Mr. Mahon may own. Additionally, Mr. Mahon receives a salary of $1,670,000.00 as EVP at United Therapeutics. Learn More about Paul A. Mahon's net worth.
How old is Paul A. Mahon?
Mr. Mahon is currently 58 years old. There are 4 older executives and no younger executives at United Therapeutics. The oldest executive at United Therapeutics is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO, who is 67 years old. Learn More on Paul A. Mahon's age.
What is Paul A. Mahon's salary?
As the EVP of United Therapeutics Co., Mr. Mahon earned a total compensation package of $4,101,226.00 in 2020. Mr. Mahon earned a salary of $908,077.00, non-equity compensation of $737,880.00, and other compensation of $22,400.00.There are 2 executives that earn more than Mr. Mahon. The highest earning executive at United Therapeutics is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO, who commands a salary of $3,510,000.00 per year. Learn More on Paul A. Mahon's salary.
How do I contact Paul A. Mahon?
Has Paul A. Mahon been buying or selling shares of United Therapeutics?
Within the last three months, Paul A. Mahon has sold $5,057,787.12 of United Therapeutics stock. Most recently, Paul A. Mahon sold 6,000 shares of the business's stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $203.34, for a transaction totalling $1,220,040.00. Following the completion of the sale, the executive vice president now directly owns 36,397 shares of the company's stock, valued at $7,400,965.98. Learn More on Paul A. Mahon's trading history.
Who are United Therapeutics' active insiders?
Are insiders buying or selling shares of United Therapeutics?
During the last twelve months, insiders at the biotechnology company sold shares 39 times. They sold a total of 179,338 shares worth more than $36,611,199.55. The most recent insider tranaction occured on September, 22nd when EVP Paul A Mahon sold 6,000 shares worth more than $1,220,040.00. Insiders at United Therapeutics own 12.4 % of the company. Learn More about insider trades at United Therapeutics.
Information on this page was last updated on 9/22/2022.
Paul A. Mahon Insider Trading History at United Therapeutics
|Transaction Date||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
United Therapeutics Company Overview
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
50 Day Range
2 Week Range